EQL Pharma Dirección
Dirección controles de criterios 1/4
El CEO de EQL Pharma's es Axel Schorling, nombrado en Aug 2022, tiene una permanencia de 1.83 años. posee directamente un 1.07% de las acciones de la empresa, con un valor de SEK15.55M. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 5.1 años, respectivamente.
Información clave
Axel Schorling
Chief Executive Officer (CEO)
n/a
Compensación total
Porcentaje del salario del CEO | n/a |
Permanencia del CEO | 1.9yrs |
Participación del CEO | 1.1% |
Permanencia media de la dirección | 1.9yrs |
Promedio de permanencia en la Junta Directiva | 5.2yrs |
Actualizaciones recientes de la dirección
Recent updates
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
Jun 13EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
May 14EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?
Dec 28What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?
Dec 11EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment
Nov 22CEO
Axel Schorling (38 yo)
1.9yrs
Permanencia
Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Founder & Chairman | 18.5yrs | SEK 1.50m | sin datos | |
President & CEO | 1.9yrs | sin datos | 1.07% SEK 17.7m | |
Chief Financial Officer | 2.6yrs | sin datos | 0.047% SEK 779.8k | |
Chief Operating Officer | 1.9yrs | sin datos | 0.052% SEK 863.4k | |
Chief Commercial Officer | no data | sin datos | 0.88% SEK 14.6m | |
Chief Business Development Officer | 1.3yrs | sin datos | sin datos |
1.9yrs
Permanencia media
50yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de EQL no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Founder & Chairman | 18.5yrs | SEK 1.50m | sin datos | |
Non Independent Director | 9.5yrs | sin datos | sin datos | |
Independent Director | 4.5yrs | sin datos | 0.0086% SEK 142.0k | |
Independent Director | 5.9yrs | sin datos | 0.034% SEK 568.0k | |
Independent Director | 3.5yrs | sin datos | 0.034% SEK 568.0k | |
Independent Director | 3.5yrs | sin datos | sin datos |
5.2yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de EQL se considera experimentada (5.1 años de antigüedad promedio).